Insertional Gene Activation by Lentiviral and Gammaretroviral Vectors
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Gammaretroviral and lentiviral vectors are promising tools for gene therapy, but they can be oncogenic. The development of safer vectors depends on a quantitative assay for insertional mutagenesis. Here we report a rapid, inexpensive, and reproducible assay which uses a murine cell line to measure the frequency of interleukin-3 (IL-3)-independent mutants. Lentiviral and gammaretroviral vectors cause insertional mutagenesis at similar frequencies; however, they use different mechanisms. Human immunodeficiency virus (HIV)-based vectors generate mutants by insertion only into the growth hormone receptor ( Ghr ) locus. The HIV enhancer/promoter is active in the absence of the HIV Tat protein in this locus, and an HIV/ Ghr spliced transcript expresses GHR and cells respond to GH. Deletion of the enhancer/promoter in a self-inactivating HIV-based vector prevents this mechanism of insertional mutagenesis. In contrast, gammaretroviral vectors insert into other loci, including IL-3 and genes identified as common insertion sites in the Retroviral Tagged Cancer Gene Database (RTCGD).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, insertional mutagenesis has been found in clinical trials with lentiviral vectors, prompting a detailed study of genotoxicity assays of all integrated vectors [76,77].”
From Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through (2022) · cites this paper as [77]
Citations
Cites
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587 · cited 1×
“For example, patients with common gamma-chain deficiency treated with a gammaretroviral vector have developed leukemia following vector insertion in oncogenic loci (13).”
BackgroundGene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G. D. S., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.-L., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,167 · cited 2×
“Because such vectors integrate into cellular DNA, transduction of patients’ bone marrow stem cells has been used to modify progeny cells of the hematopoietic system, leading to correction of inherited immunodeficiencies (1, 6, 23).”
BackgroundMethodTranscription Start Regions in the Human Genome Are Favored Targets for MLV Integration
Wu, X., Li, Y., Crise, B., & Burgess, S. M. (2003) · Science · doi:10.1126/science.1083413 · Cited by 1,305 · cited 6×
“G18 2 N Il3 16187 11 2,607 bp downstream Cytokine/growth factor activity N Fbxo9 71538 9 3,183 bp upstream Ubiquitin-protein ligase activity N Ick 56542 5,744 bp upstream Protein kinase activity, signal transduction Control CNCG 2 1 Y Tpm3 59069 3 8,408 bp, intron 2-3 Regulation of muscle contraction 1 CNCG 6 1 N Mll2…”
BackgroundMethodInfluentialOtt, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051 · cited 2×
“Because such vectors integrate into cellular DNA, transduction of patients’ bone marrow stem cells has been used to modify progeny cells of the hematopoietic system, leading to correction of inherited immunodeficiencies (1, 6, 23).”
BackgroundRetroviral DNA Integration: ASLV, HIV, and MLV Show Distinct Target Site Preferences
Mitchell, R. S., Beitzel, B. F., Schroder, A. R. W., Shinn, P., Chen, H., Berry, C. C., Ecker, J. R., & Bushman, F. D. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020234 · Cited by 976 · cited 1×
“However, MLV tends to integrate near the transcription start site, and HIV shows a stronger preference for expressed genes (20, 38).”
BackgroundCorrection of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning
Aiuti, A., Slavin, S., Aker, M., Ficara, F., Deola, S., Mortellaro, A., Morecki, S., Andolfi, G., Tabucchi, A., Carlucci, F., et al. (2002) · Science · doi:10.1126/science.1070104 · Cited by 975 · cited 1×
“Because such vectors integrate into cellular DNA, transduction of patients’ bone marrow stem cells has been used to modify progeny cells of the hematopoietic system, leading to correction of inherited immunodeficiencies (1, 6, 23).”
BackgroundMontini, E., Cesana, D., Schmidt, M., Sanvito, F., Ponzoni, M., Bartholomae, C., Sergi, L. S., Benedicenti, F., Ambrosi, A., Di Serio, C., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1216 · Cited by 701 · cited 1×
“Retroviral-vector insertional oncogenesis has been quantitated in mice either by using vectors expressing an oncogene (11, 18) or mutant, tumor-prone mice (22, 29).”
BackgroundA transient three-plasmid expression system for the production of high titer retroviral vectors
Soneoka, Y., Cannon, P. M., Ramsdale, E. E., Griffiths, J. C., Romano, G., Kingsman, S. M., & Kingsman, A. J. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.4.628 · Cited by 690
Palacios, R., & Steinmetz, M. (1985) · Cell · doi:10.1016/s0092-8674(85)80053-2 · Cited by 688
Gene transfer in humans using a conditionally replicating lentiviral vector
Levine, B. L., Humeau, L. M., Boyer, J., MacGregor, R.-R., Rebello, T., Lu, X., Binder, G. K., Slepushkin, V., Lemiale, F., Mascola, J. R., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608138103 · Cited by 501 · cited 1×
“In a recent AIDS gene therapy clinical trial, a WT HIV-1 LTR lentiviral vector was used to drive antisense RNA against the HIV-1 envelope, so that Tat would activate expression in HIVinfected cells (17).”
Method
Cited by
Montini, E., Cesana, D., Schmidt, M., Sanvito, F., Bartholomae, C. C., Ranzani, M., Benedicenti, F., Sergi, L. S., Ambrosi, A., Ponzoni, M., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37630 · Cited by 571
“The mechanism of splicing mediated activation of oncogene by LVs with active LTRs has been recently described in a cell-culture assay for insertional mutagenesis (51).”
Modlich, U., Navarro, S., Zychlinski, D., Maetzig, T., Knoess, S., Brugman, M. H., Schambach, A., Charrier, S., Galy, A., Thrasher, A. J., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.179 · Cited by 387
Lentiviral Vectors in Gene Therapy: Their Current Status and Future Potential
Escors, D., & Breckpot, K. (2010) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-010-0063-4 · Cited by 344
“Lentivectors also exhibit insertional mutagenesis in animal models and cell-based systems prone to oncogenesis (Bokhoven et al. 2009), although overall they seem to be less mutagenic than their oncoretrovirus counterparts (Hematti et al.”
Viral vectors for gene delivery to the central nervous system
Lentz, T. B., Gray, S. J., & Samulski, R. J. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.09.014 · Cited by 271
Biffi, A., Bartolomae, C. C., Cesana, D., Cartier, N., Aubourg, P., Ranzani, M., Cesani, M., Benedicenti, F., Plati, T., Rubagotti, E., et al. (2011) · Blood · doi:10.1182/blood-2010-09-306761 · Cited by 216
Viral Vectors: The Road to Reducing Genotoxicity
David, R. M., & Doherty, A. T. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfw220 · Cited by 170
“…and upregulation of, the Evi1 gene in primary mouse bone marrow cells, which are cultured for an extended period (Modlich et al., 2006), and another that measures the frequency of interleukin-3 (IL-3)-independent mutants in a murine cell line that is normally IL-3-dependent (Bokhoven et al., 2009).”
BackgroundInfluentialBiology of adeno-associated viral vectors in the central nervous system
Murlidharan, G., Samulski, R. J., & Asokan, A. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00076 · Cited by 154
Biosafety Features of Lentiviral Vectors
Schambach, A., Zychlinski, D., Ehrnstroem, B., & Baum, C. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.229 · Cited by 173
“…underline the concern that intragenic insertion events of lentiviral vectors can have functional consequences (Table 2) (Arumugam et al., 2009a; Bokhoven et al., 2009; Modlich et al., 2009; Montini et al., 2009; Knight et al., 2010; Cesana et al., 2012; Heckl et al., 2012; Knight et al., 2012;…”
MicroRNA-210 overexpression induces angiogenesis and neurogenesis in the normal adult mouse brain
Zeng, L., He, X., Wang, Y., Tang, Y., Zheng, C., Cai, H., Liu, J., Wang, Y., Fu, Y., & Yang, G.-Y. (2014) · Gene Therapy · doi:10.1038/gt.2013.55 · Cited by 167
Gammaretroviral Vectors: Biology, Technology and Application
Maetzig, T., Galla, M., Baum, C., & Schambach, A. (2011) · Viruses · doi:10.3390/v3060677 · Cited by 184
“An important avenue and challenge for gene therapy with integrating (retroviral) vectors will be the development of better assays to predict more precisely insertional adverse events (including upregulation of neighboring genes and also gene disruption), ideally both in cell culture based systems [202,206] and small a…”
BackgroundCesana, D., Sgualdino, J., Rudilosso, L., Merella, S., Naldini, L., & Montini, E. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62189 · Cited by 127
“…and gamma-retroviral/lentiviral vectors ( γ RV/LVs) with active long terminal repeats (LTRs) integrate downstream of the promoters of cellular genes in the same transcriptional orientation, gene transcription is put under the control of the viral promoter present in the 5 ′ or 3 ′ LTR (4, 11).”
The Inside Out of Lentiviral Vectors
Durand, S., & Cimarelli, A. (2011) · Viruses · doi:10.3390/v3020132 · Cited by 98
“vectors, increases the safety of lentiviral vectors due to the lack of expression of ψ-bearing mRNAs in transduced cells and to the minimization of gene activation in the proximity of the provirus integration site [122].”
BackgroundState-of-the-Art Lentiviral Vectors for Research Use: Risk Assessment and Biosafety Recommendations
Pauwels, K., Gijsbers, R., Toelen, J., Schambach, A., Willard-Gallo, K., Verheust, C., Debyser, Z., & Herman, P. (2009) · Current Gene Therapy · doi:10.2174/156652309790031120 · Cited by 106
“In addition, the risk associated to transactivation of neighbouring genome sequences must also be considered as in vitro studies suggest vectors' enhancer-promoter elements have a determinant role in the insertional transformation capacity of LV [18, 39-41].”
BackgroundRahim, A. A., Wong, A. M. S., Howe, S. J., Buckley, S. M. K., Acosta-Saltos, A. D., Elston, K. E., Ward, N. J., Philpott, N. J., Cooper, J. D., Anderson, P. N., et al. (2009) · Gene Therapy · doi:10.1038/gt.2008.186 · Cited by 101
Stephen, S. L., Freestone, K., Dunn, S., Twigg, M. W., Homer‐Vanniasinkam, S., Walker, J. H., Wheatcroft, S. B., & Ponnambalam, S. (2010) · International Journal of Hypertension · doi:10.4061/2010/646929 · Cited by 112
“In the case of retro- and lentiviral vectors, the promoter enhancer elements located in the viral termini appear responsible for this altered host gene expression profile [171, 172].”
BackgroundSelf-citationRecent progress in satellite cell/myoblast engraftment – relevance for therapy
Briggs, D. A., & Morgan, J. E. (2013) · FEBS Journal · doi:10.1111/febs.12273 · Cited by 101
Cheng, S., Nethi, S. K., Rathi, S., Layek, B., & Prabha, S. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.259796 · Cited by 91
“Moreover, viral transduction methods for genetic engineering of MSCs pose high risk of chromosomal instability (Takeuchi et al., 2007), insertional mutagenesis (Bokhoven et al., 2009), and proto-oncogene activation (Modlich et al., 2009) despite inherent high transfection efficiency.”
BackgroundImmunization delivered by lentiviral vectors for cancer and infectious diseases
Hu, B., Tai, A., & Wang, P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00967.x · Cited by 89
“In another study (119), a murine line was used to observe the frequency of IL-3-independent mutants and insertional mutagenesis by LVs was also seen.”
MethodKarwacz, K., Mukherjee, S., Apolonia, L., Blundell, M. P., Bouma, G., Escors, D., Collins, M. K., & Thrasher, A. J. (2009) · Journal of Virology · doi:10.1128/jvi.02519-08 · Cited by 87
“However, we have detected lentiviral vector insertional gene activation in a cell line assay (2), and upregulation of adjacent genes by selfinactivating lentivectors has been reported (10).”
BackgroundSelf-citationUse of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative Diseases
Wyse, R., Dunbar, G., & Rossignol, J. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15021719 · Cited by 80
“the rate of mutagenesis of a retrovirus and a lentivirus, albeit these were mediated through different mechanisms [77].”
BackgroundContext-aware synthetic biology by controller design: Engineering the mammalian cell
Shakiba, N., Jones, R. D., Weiss, R., & Vecchio, D. D. (2021) · Cell Systems · doi:10.1016/j.cels.2021.05.011 · Cited by 88
“Journal of Biological Engineering 9, p. 5.1208 Bokhoven, Marieke, Sam L. Stephen, Sean Knight, Evelien F. Gevers, Iain C. Robinson, Yasuhiro Takeuchi, and Mary1209 K. Collins (2009).”
InfluentialUse of HIV as a gene transfer vector.
Pluta, K. D., & Kacprzak, M. M. (2009) · Acta Biochimica Polonica · doi:10.18388/abp.2009_2490 · Cited by 93
“tually, in the recently developed cell culture assay for insertional mutagenesis, SIN deletion of the promoter/enhancer region from HIV-based vector LTRs resulted in a complete abrogation of the insertional gene activation, frequently observed for both lentiviral and gamma-retroviral vectors (Bokhoven et al., 2009).”
BackgroundSelf-Inactivating Alpharetroviral Vectors with a Split-Packaging Design
Suerth, J. D., Maetzig, T., Galla, M., Baum, C., & Schambach, A. (2010) · Journal of Virology · doi:10.1128/jvi.00182-10 · Cited by 88
Carbon nanotubes in drug delivery: focus on infectious diseases
Rosen, Y., & Elman, N. M. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240902865579 · Cited by 69
“Viral delivery, albeit achieving high levels of gene expression, has several noteworthy disadvantages such as induction of immunogenic reactions, induction of inflammatory reactions which render transient transgene expression and potential oncogenic effects [31,32,82,83].”
BackgroundNon-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through
Gurumoorthy, N., Nordin, F., Tye, G. J., Wan Kamarul Zaman, W. S., & Ng, M. H. (2022) · Biomedicines · doi:10.3390/biomedicines10010107 · Cited by 69
Time to evolve: predicting engineered T cell-associated toxicity with next-generation models
Donnadieu, E., Luu, M., Alb, M., Anliker, B., Arcangeli, S., Bonini, C., Angelis, B. D., Choudhary, R., Espie, D., Galy, A. H. M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003486 · Cited by 69
Advancements in the design and scalable production of viral gene transfer vectors
Sharon, D., & Kamen, A. (2018) · Biotechnology and Bioengineering · doi:10.1002/bit.26461 · Cited by 59
“However, the integrative nature of the vector also introduces the risk of insertional mutagenesis (IM), particularly proto-oncogene activation (Bokhoven et al., 2009).”
BackgroundPreventing and exploiting the oncogenic potential of integrating gene vectors
Modlich, U., & Baum, C. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38831 · Cited by 66
Herpes Simplex Virus Vectors for Gene Transfer to the Central Nervous System
Artusi, S., Miyagawa, Y., Goins, W. F., Cohen, J. B., & Glorioso, J. C. (2018) · Diseases · doi:10.3390/diseases6030074 · Cited by 59
Stem cells to treat muscular dystrophies – Where are we?
Meng, J., Muntoni, F., & Morgan, J. E. (2010) · Neuromuscular Disorders · doi:10.1016/j.nmd.2010.10.004 · Cited by 64
“But they have the drawbacks of a relatively small gene insert size [59,60] and possible insertional mutagenesis in the host genome [61,62].”
BackgroundMillington, M., Arndt, A. J., Boyd, M. P., Applegate, T. L., & Shen, S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006461 · Cited by 68
The old and the new: Prospects for non-integrating lentiviral vector technology
Apolonia, L. (2020) · Viruses · doi:10.3390/v12101103 · Cited by 58
“It was then evident that further vector development was necessary to reduce these adverse outcomes and the self-inactivating (SIN) vector design was shown to improve the biosafety profiles of these vectors [20,21].”
BackgroundKwiatkowski, J. L., Walters, M. C., Hongeng, S., Yannaki, E., Kulozik, A. E., Kunz, J. B., Sauer, M. G., Thrasher, A. J., Thuret, I., Lal, A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01884-1 · Cited by 61
Retroviral and Lentiviral Vectors for the Induction of Immunological Tolerance
Dufait, I., Liechtenstein, T., Lanna, A., Bricogne, C., Laranga, R., Padella, A., Breckpot, K., & Escors, D. (2012) · Scientifica · doi:10.6064/2012/694137 · Cited by 66
“e removal of the proviral LTRs can partially solve this problem (self-inactivating lentivectors [20, 131, 132], since the viral enhancers that they contain strongly up-regulate proto-oncogenes and also lead to aberrant transcription and alternative splicing [128, 129, 133, 134].”
Gellhaus, B., Böker, K. O., Schilling, A. F., & Saul, D. (2023) · Cells · doi:10.3390/cells12242787 · Cited by 58
“For an observational time of 8 weeks, a stable knockdown was observed, indicating its potential for gene silencing [132] (Figure 5).”
BackgroundPace, M. J., Williams, J., Kurioka, A., Gerry, A. B., Jakobsen, B. K., Klenerman, P., Nwokolo, N. C., Fox, J., Fidler, S. J., Frater, J., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005782 · Cited by 54
“Expression levels were then normalized to 18s rRNA levels measured using the previously described primers 5’TCGAGGCCCTGTAATTGGAA-3’ and 5’GAGTCCTGCGTCGAGA GAGC [33].”
MethodDe Ravin, S. S., Liu, S., Sweeney, C. L., Brault, J., Whiting-Theobald, N., Ma, M., Liu, T., Choi, U., Lee, J., O’Brien, S. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31344-x · Cited by 51
Lobo, E. O., Zhang, Z., & Shively, J. E. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0109037 · Cited by 50
“Importantly, our studies do not include a lentivirus control, as virus integration is random in the genome, and the potential complication of insertional mutagenesis is therefore also random [ 65 ].”
BackgroundViral vectors for gene therapy and gene modification approaches
Merten, O., & Gaillet, B. (2015) · Biochemical Engineering Journal · doi:10.1016/j.bej.2015.09.005 · Cited by 57
Hu, B., Dai, B., & Wang, P. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.08.012 · Cited by 45
“Despite the desirable advantage of lentiviral vectors to effectively deliver transgenes into DCs, vector integration has provoked safety concerns over the consequences of insertional mutagenesis [14,15].”
BackgroundLentiviral Vectors for Cancer Immunotherapy and Clinical Applications
Liechtenstein, T., Pérez‐Janices, N., & Escors, D. (2013) · Cancers · doi:10.3390/cancers5030815 · Cited by 52
“Lentivectors lead to prolonged transgene expression due to stable genome integration within transcriptionally active chromatin sites [26].”
BackgroundVink, C. A., Counsell, J. R., Perocheau, D. P. B., Karda, R., Buckley, S. M. K., Brugman, M. H., Galla, M., Schambach, A., McKay, T. R., Waddington, S. N., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.04.028 · Cited by 46
“Despite these advantages, there is scope for further improvement of lentiviral vector technology, given their reported interference with the human genome owing to the concurrent delivery of wild-type HIV cis elements.(19,20,41,42)”
Knight, S., Zhang, F., Müller-Kuller, U., Bokhoven, M., Gupta, A., Broughton, T., Sha, S., Antoniou, M. N., Brendel, C., Grez, M., et al. (2012) · Journal of Virology · doi:10.1128/jvi.00485-12 · Cited by 45
“Selected A2UCOE-based lentiviral vectors were tested in an insertional mutagenesis assay using IL-3-dependent Bcl-15 cells (Fig.”
BackgroundMethodInfluentialSelf-citationKhatib, M. M. E., Ohmine, S., Jacobus, E. J., Tonne, J. M., Morsy, S. G., Holditch, S. J., Schreiber, C. A., Uetsuka, K., Fusaki, N., Wigle, D. A., et al. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0017 · Cited by 43
Recent Gene Therapy Advancements for Neurological Diseases
The University of North Carolina at Chapel Hill University Libraries (2013) · PubMed · doi:10.17615/ze6f-8f23 · Cited by 49
Periostin Secreted by Mesenchymal Stem Cells Supports Tendon Formation in an Ectopic Mouse Model
Noack, S., Seiffart, V., Willbold, E., Laggies, S., Winkel, A., Shahab‐Osterloh, S., Floerkemeier, T., Hertwig, F., Steinhoff, C., Nuber, U. A., et al. (2014) · Stem Cells and Development · doi:10.1089/scd.2014.0124 · Cited by 41
“So, human im-munodeficiency virus (HIV)–based vectors may integrate into the growth hormone receptor locus [28].”
Genetic Engineering of Mesenchymal Stem Cells for Regenerative Medicine
Nowakowski, A., Walczak, P., Janowski, M., & Lukomska, B. (2015) · Stem Cells and Development · doi:10.1089/scd.2015.0062 · Cited by 38
“Viral transduction meth-ods, despite their reported high efficiency of transgene expression, are unlikely to be allowed in clinical trials because of their high risk of insertional mutagenesis [274], chromosomal instability [275], and proto-oncogene activation.”
Kim, H. S., Hwang, G., Lee, H. K., Bae, T., Park, S.-H., Kim, Y. J., Lee, S., Park, J.-H., Bae, S., & Hur, J. K. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.10.012 · Cited by 37
Aerosol gene delivery using viral vectors and cationic carriers forin vivolung cancer therapy
Hong, S., Park, S. J., Lee, S., Cho, C. S., & Cho, M. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.986454 · Cited by 43
“However, after lentiviral vector administration, insertional mutagenesis could be promoted by the activation of cellular oncogenes [23].”
BackgroundHung, C.-J., Yao, C., Cheng, F., Wu, M., Wang, T., & Hwang, S. (2010) · Cytotherapy · doi:10.3109/14653240903555827 · Cited by 36
Montiel-Equihua, C., Zhang, L., Knight, S., Saadeh, H., Scholz, S., Carmo, M., Alonso-Ferrero, M. E., Blundell, M. P., Monkeviciute, A., Schulz, R., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.50 · Cited by 39
“IL-3 independent mutant Bcl-15 cells, where the vector inserted in the growth hormone receptor gene (Ghr), activated Ghr by a vector splicing donor site being spliced to Ghr and caused cytokine-independent cell growth, were selected and analysed 12 , 13 .”
Self-citationBlack, A., Vasireddy, V., Chung, D. C., Maguire, A. M., Gaddameedi, R., Tolmachova, T., Seabra, M., & Bennett, J. (2014) · The Journal of Gene Medicine · doi:10.1002/jgm.2768 · Cited by 32
“immediately downstream of the integration site (44-46).”
Knight, S., Bokhoven, M., Collins, M. K., & Takeuchi, Y. (2010) · Journal of Virology · doi:10.1128/jvi.02476-09 · Cited by 34
“Previously, we developed an assay to assess IM based on the cell line Bcl-15, which is dependent on interleukin-3 (IL-3) for survival (3, 4).”
BackgroundMethodSelf-citationYang, H., Qing, K., Keeler, G. D., Yin, L., Mietzsch, M., Ling, C., Hoffman, B. E., Agbandje‐McKenna, M., Tan, M., Wang, W., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.03.009 · Cited by 32
The genomic risk of somatic gene therapy
Kustikova, O. S., Brugman, M. H., & Baum, C. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.06.003 · Cited by 35
Lentiviral Gene Therapy Vectors: Challenges and Future Directions
Tomás, H. A., Ana, F., Paula, M., & Coroadinha, A. S. (2013) · InTech eBooks · doi:10.5772/52534 · Cited by 45
“This transcrip‐ tional inactivation offered by the SIN design presents several safety advantages: prevents the formation of potentially packageable viral transcripts from the 5 ́LTR and consequently prevents vector mobilization by prior infection with a replicative retrovirus [39,42]; reduces the risk of insertional m…”
BackgroundProgress and prospects: Foamy virus vectors enter a new age
Erlwein, O. W., & McClure, M. O. (2010) · Gene Therapy · doi:10.1038/gt.2010.95 · Cited by 30
Hu, B., Yang, H., Dai, B., Tai, A., & Wang, P. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.012 · Cited by 27
“Even though lentiviral vectors retain insertional activation, they have been shown to exhibit low genotoxicity in certain mouse models (Montini et al., 2006; Bokhoven et al., 2009), which makes them favorable for immunological applications.”
Synthetic biology and occupational risk
Howard, J., Murashov, V. V., & Schulte, P. A. (2017) · Journal of Occupational and Environmental Hygiene · doi:10.1080/15459624.2016.1237031 · Cited by 26
“[127] The development of an assay that quantitates insertional mutagenesis can help produce safer viral vectors.[128] Finally, a largely theoretical intrinsic biocontainment method involves engineering organisms with chromosomes made not from DNA and RNA, but from xeno (“stranger”) nucleic acids or XNA.”
BackgroundVargas, F. A., Kochan, G. T., Breckpot, K., Stephenson, H. N., & Escors, D. (2012) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152012798764679 · Cited by 28
Chira, S., Nutu, A. M., Isachesku, E., Bica, C., Pop, L., Ciocan, C. A., & Berindan‐Neagoe, I. (2022) · Cells · doi:10.3390/cells11182781 · Cited by 27
“Besides CRISPR/Cas9, inserting foreign genetic material can be achieved either by retroor lentiviral vectors [87,88] or by DNA transposons [89,90], however, the insertion locus is quite random, and even can result in activation of a malignant phenotype, as in the case of lentiviral vectors [91].”
BackgroundWang, C.-J., Qu, C., Zhang, J., Fu, P., Guo, S., & Tang, R. (2014) · The Anatomical Record · doi:10.1002/ar.22988 · Cited by 24
“Second, Lentivectors lead to prolonged transgene expression due to integration into the host genome (Bokhoven et al., 2009).”
BackgroundUsing Gene Editing to Establish a Safeguard System for Pluripotent Stem-Cell-Based Therapies
Wu, Y., Chang, T., Long, Y., Huang, H., KANDEEL, F. R., & Yee, J. (2019) · iScience · doi:10.1016/j.isci.2019.11.038 · Cited by 24
Gene therapy using retrovirus vectors: vector development and biosafety at clinical trials
Knayo, D. O. I., & Takeuchi, Y. (2015) · Uirusu · doi:10.2222/jsv.65.27 · Cited by 23
Self-citationAhmed, S., Waddington, S. N., Boza-Moran, M.-G., & Yáñez‐Muñoz, R. J. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.12.029 · Cited by 20
“Albeit lower, some risk of insertional mutagenesis is also present using integrating lentiviral vectors [4].”
BackgroundFoamy Virus Vectors for HIV Gene Therapy
Olszko, M. E., & Trobridge, G. D. (2013) · Viruses · doi:10.3390/v5102585 · Cited by 19
“SIN vectors are less likely to activate nearby genes than nonSIN vectors [25].”
BackgroundSerra, J., Alves, C. P. A., Brito, L., Monteiro, G. A., Cabral, J. M. S., Prazeres, D. M. F., & da Silva, C. L. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.154 · Cited by 20
“51,52 55 Minicircles, on the other hand, can be less immunogenic (and thus safer) due to the reduced content of bacterial sequences rich in unmethylated CpG residues that may activate the immune system, and are more efficiently delivered into stem cells by microporation due to their lower size…”
Immune modulation by genetic modification of dendritic cells with lentiviral vectors
Liechtenstein, T., Pérez‐Janices, N., Bricogne, C., Lanna, A., Dufait, I., Goyvaerts, C., Laranga, R., Padella, A., Vargas, F. A., Baratchian, M., et al. (2013) · Virus Research · doi:10.1016/j.virusres.2013.05.007 · Cited by 24
He, W., Chen, L., Huang, Y., Xu, Z., Xu, W., Ding, N., & Chen, J. (2019) · Cytokine · doi:10.1016/j.cyto.2019.03.020 · Cited by 18
New Tools for Epilepsy Therapy
Falcicchia, C., Simonato, M., & Verlengia, G. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00147 · Cited by 18
“However, the downside is the possibility of getting insertional mutagenesis (Bokhoven et al., 2009).”
BackgroundThe science and practice of current environmental risk assessment for gene therapy: a review
Liu, F. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.04.067 · Cited by 16
Altun, H. Y., Seçilmiş, M., Yang, F., Çağlar, T. A., Vatandaşlar, E., Toy, M. F., Vilain, S., Mann, G. E., Öztürk, G., & Eroğlu, E. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.05.021 · Cited by 16
Browning, D. L., Collins, C. P., Hocum, J. D., Leap, D. J., Rae, D. T., & Trobridge, G. D. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.110 · Cited by 14
An MBPhD programme in the UK: the UCL experience
Stewart, G. W. (2012) · Clinical Medicine · doi:10.7861/clinmedicine.12-6-526 · Cited by 14
Karpov, D. S., Demidova, N. A., Kulagin, K. A., Shuvalova, A. I., Kovalev, M. A., Simonov, R. A., Карпов, В. Л., Snezhkina, A. V., Kudryavtseva, A. V., Рафаиловна, К. Р., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314847 · Cited by 14
“Delivery of CRISPR/Cas components in retroviral vectors is very efficient, but raises safety concerns due to integration mutagenesis of retroviral vectors [27,28].”
BackgroundEvidence for the in vivo safety of insulated foamy viral vectors
Browning, D. L., Everson, E. M., Leap, D. J., Hocum, J. D., Wang, H., Stamatoyannopoulos, G., & Trobridge, G. D. (2016) · Gene Therapy · doi:10.1038/gt.2016.88 · Cited by 13
“21, 22 FV vectors have a potentially safer integration profile, 17, 23, 24 integrating less frequently near transcription start sites (TSS) than gammaretroviral vectors, and less often within genes compared to lentiviral vectors.”
Pramod, R. K., & Mitra, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-21558-9 · Cited by 13
Sertkaya, H., Ficarelli, M., Sweeney, N. P., Parker, H., Vink, C. A., & Swanson, C. M. (2021) · Scientific Reports · doi:10.1038/s41598-021-91309-w · Cited by 13
Suleman, S., Payne, A. M., Bowden, J., Alhaque, S., Zahn, M., Fawaz, S., Khalifa, M. S., Jobling, S., Hay, D. C., Franco, M., et al. (2022) · Gene Therapy · doi:10.1038/s41434-022-00335-4 · Cited by 13
“These viruses have previously been used in both cell and animal assays [8, 69 – 71].”
MethodSelf-citationSweeney, N. P., Regan, C. L., Liu, J., Galleu, A., Dazzi, F., Lindemann, D., Rupar, C. A., & McClure, M. O. (2016) · Molecular Therapy · doi:10.1038/mt.2016.91 · Cited by 12
“28 Consequently, modern clinically relevant gene therapy vectors are deleted of promoter/enhancer activity from the viral long terminal repeats (LTRs) (termed self-inactivating (SIN) vectors 29 ) and employ nonviral physiological promoters to drive transgene expression.”
Venkatesan, J. K., Cai, X., Meng, W., Rey‐Rico, A., Schmitt, G., Speicher‐Mentges, S., Falentin‐Daudre, C., Leroux, A., Madry, H., Migonney, V., et al. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.329 · Cited by 11
“…contrast to findings where rAAV-hTGF-b was applied to bone marrow aspirates in a free form, showing significant, but decreasing TGF-b synthesis over time (from 113 to 16 pg/mg total proteins/24h between days 14 and 21), 27 again possibly due to the effective controlled release of rAAV from such films.”
Adeno-Associated Viral Vectors in the Treatment of Epilepsy
Mullagulova, A., Timechko, E. E., Solovyeva, V., Yakimov, A. M., Ibrahim, A., Dmitrenko, D., Sufianov, A., Sufianova, G., & Rizvanov, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212081 · Cited by 8
A Graph Based Framework to Model Virus Integration Sites
Fronza, R., Vasciaveo, A., Benso, A., & Schmidt, M. (2015) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.10.006 · Cited by 11
“Thecentralroleinintegrationsite(IS)analysesisgivenintheassess-ment of the genome-wide integration pro fi le and the identi fi cation of integration clusters that could alter gene expression.”
BackgroundSafety and Efficacy of Retroviral and Lentiviral Vectors for Gene Therapy
Cesana, D., Volpin, M., Secanechia, Y. N. S., & Montini, E. (2017) · Springer eBooks · doi:10.1007/978-3-319-53457-2_2 · Cited by 14
Lentiviral Vector Promoter is Decisive for Aberrant Transcript Formation
Scholz, S., Fronza, R., Bartholomae, C. C., Cesana, D., Montini, E., Kalle, C. V., Gil-Fariña, I., & Schmidt, M. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.162 · Cited by 10
“, reporting that the major mechanism of mutagenesis used by lentiviral vectors involves vector-mediated aberrant splicing.(38) The identification of cryptic splice sites within the vector construct allows the recoding of these sequences and reduction of residual aberrant splicing.”
Klapwijk, J. C., Río-Espínola, A. D., Libertini, S., Collin, P., Fellows, M. D., Jobling, S., Lynch, A. M., Martus, H., Vickers, C. A., Zeller, A., et al. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.033 · Cited by 9
“65,66 This group is unaware whether these assays have been used for regulatory purposes.”
Non-coding RNAs in stroke pathology, diagnostics, and therapeutics
Potemkin, N., & Clarkson, A. N. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105467 · Cited by 9
Papayanni, P. G., Psatha, N., Christofi, P., Li, X., Melo, P., Volpin, M., Montini, E., Liu, M., Kaltsounis, G., Yiangou, M., et al. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.142 · Cited by 9
Generation and Characterization of a CRISPR/Cas9-Mediated SNAP29 Knockout in Human Fibroblasts
Martens, M. C., Edelkamp, J., Seebode, C., Schäfer, M., Staehlke, S., Krohn, S., Jung, O., Escobar, H. M., Emmert, S., & Boeckmann, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105293 · Cited by 8
“Although targeted alterations may take place, other genes of the target cell genome might be affected [19].”
BackgroundSmolny, M., Rogers, M., Shafton, A. D., Rush, R. A., & Stebbing, M. J. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00079 · Cited by 9
“ORIGINAL RESEARCH ARTICLE published: 09 October 2014 doi: 10.3389/fnmol.2014.00079 Development of non-viral vehicles for targeted gene transfer into microglia via the integrin receptor CD11b”
BackgroundMethodInfluentialPossible Applications for Replicating Hiv-1 Vectors
Das, A. T., Jeeninga, R. E., & Berkhout, B. (2010) · HIV Therapy · doi:10.2217/hiv.10.20 · Cited by 7
Ha, T.-C., Stahlhut, M., Rothe, M., Paul, G., Dziadek, V., Morgan, M. A., Brugman, M. H., Fehse, B., Kustikova, O. S., Schambach, A., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.344 · Cited by 7
On the road to in vivo CAR-T success: Comparing promising viral and non-viral vectors
de la Mota, S., Suchet, L., van Wijk, M., Stibbs, D. J., Couto, P. S., & Rafiq, Q. A. (2026) · Biotechnology Advances · doi:10.1016/j.biotechadv.2026.108907 · Cited by 6
Application Advances of Lentiviral Vectors: From Gene Therapy to Vaccine Development
Fang, E., He, G., Chang, Y., He, Q., Chen, P., & Hu, K. (2025) · Molecular Biotechnology · doi:10.1007/s12033-025-01472-y · Cited by 8
Targeted cytokine delivery for cancer therapy through engineered mesenchymal stem cells
Yeganeh, P., Forghani, S., Pouresmaeil, L., Parhizkar, F., & Jafari, D. (2025) · Gene Reports · doi:10.1016/j.genrep.2025.102199 · Cited by 8
Modeling of Gene Therapy for Regenerative Cells Using Intelligent Agents
Adly, A. S., Aboutabl, A. E., & Ibrahim, M. S. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-7046-6_32 · Cited by 6
“Since stem cell research began, there has been a hope that use of those cells may help alleviate some of the trauma left behind by genetic diseases [11–13].”
BackgroundBroughton, K. M., Korski, K., Echeagaray, O., Adamson, R. M., Dembitsky, W. P., Lu, Z., Schaefer, E., & Sussman, M. A. (2019) · Gene Therapy · doi:10.1038/s41434-019-0084-5 · Cited by 6
Gene Therapy in Skin: Choosing the Optimal Viral Vector
Teo, E. H., Cross, K. J., Bomsztyk, E. D., Lyden, D. C., & Spector, J. A. (2009) · Annals of Plastic Surgery · doi:10.1097/sap.0b013e31819fafbd · Cited by 6
“However, the relatively random location of insertion within the host cell genome may have significant deleterious consequences and could theoretically result in cell death or carcinogenic transformation.(13) Safety concerns of lentiviral vectors remains an issue that must be resolved before widespread clinical use is…”
BackgroundSkuk, D. (2013) · ISRN Transplantation · doi:10.5402/2013/582689 · Cited by 6
“The problem of lentiviruses is however that they can carry a relatively small gene [205], and that there is the risk of insertional mutagenesis [206].”
BackgroundPromises and Challenges in Hematopoietic Stem Cell Gene Therapy
Kohlscheen, S., Bonig, H. B., & Modlich, U. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.141 · Cited by 5
Metadata
- Authors
- Bokhoven, M., Stephen, S. L., Knight, S., Gevers, E. F., Robinson, I. C., Takeuchi, Y., & Collins, M. K.
- Affiliations
- University College London (GB)
- National Institute for Medical Research (GB)
- Corresponding author
- Collins, Mary K.
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2009-01
- Volume
- 83
- Issue
- 1
- Pages
- 283-294
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- PMC
- PMC2612344
- OpenAlex
- W2134056794
- Semantic Scholar
- 00dac6f887ef7c0e93ed3839c2a8065d747910a7
- Cited by
- 138
- References
- 39
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 6 · 2023: 2 · 2022: 9 · 2021: 7 · 2020: 4 · 2019: 6 · 2018: 8 · 2017: 7 · 2016: 8 · 2015: 8 · 2014: 8 · 2013: 9 · 2012: 12
- FWCI
- 6.86
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Virology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Health and Safety Executive
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- insertional mutagenesis, lentiviral vectors, gammaretroviral vectors, gene therapy safety, oncogenicity, HIV-based vectors, self-inactivating vectors, Tat protein, insertion site mapping
- MeSH terms
- Animals, Cell Line, Genetic Vectors, Genetic Therapy, Lentivirus, Mutagenesis, Insertional, Gammaretrovirus, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.